Race Oncology Limited announced that Mr. Damian Clarke-Bruce has been appointed as Chief Executive Officer, effective 1 February 2023. Mr. Phil Lynch will return to his prior role as a Non-Executive Director of Race Oncology and will work closely with Mr. Clarke-Bruce to ensure a smooth and effective leadership transition. Dr Tillett will continue in his leadership role as Chief Scientific Officer and Executive Director.

An extensive internal review in 2022 of the commercialisation and partnership opportunity provided by Zantrene identified the need for a full-time, highly experienced executive with global pharma partnership and drug development capability to advance Race. Coulter Partners, a specialised international pharma/biotech executive recruitment firm was appointed to identify suitable candidates. This process, over a multi-month period, included a diligent evaluation of capability and requirements by the Race Board and management team.

Mr. Clarke-Bruce brings deep global experience in drug commercialisation and portfolio strategy. He has held executive roles at all stages of the drug development process, from pre-clinical evaluation through to successful commercial launch. He has identified and defined new markets for pharma assets and has overseen product registration, access and reimbursement, medical marketing, and commercial sale.

He brings an extensive network from within the pharmaceutical industry, as well as exceptional relationships with key opinion leaders across several therapeutic areas, including oncology, haematology and immunology.